Drugs / Dual-targeting BCMA-GPRC5D CAR-T cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07003568 | May 2025 → May 2027 expected | refractory plasma cell neoplasm | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-targeting BCMA-GPRC5D CAR-T cell therapy | “Dual-targeting BCMA-GPRC5D CAR-T cell therapy” NCT07003568 ↗ |
| Modality | Cell therapy | “BCMA - GPRC5D CAR-T cell therapy” NCT07003568 ↗ |
| Target | GPRC5D | “BCMA - GPRC5D CAR-T cell therapy” NCT07003568 ↗ |